FAIRFIELD, CT, June 03, 2013 (Press-News.org) In their May 17th "Digital Crave" shopping blog, Yahoo! included the new ThiPad thigh-mounted tablet stand in a piece titled "The Worst iPad Accessories--Ever."
"And they did us a favor," says Jerry McTigue, creator of the ThiPad. "Because the hundreds of readers who went to the ThiPad.com website to see just how bad a product it was, actually discovered how good it was. And they started buying it."
McTigue believes that if the ThiPad can gain converts with horrible publicity like that, there's no telling what it would do if given a fair evaluation. He maintains that the so-called reporter never bothered to obtain a sample of the product and try it out. "Rather, he based his snide judgements on website images and a pre-prejudiced need to round up targets for a snark attack," says McTigue. "This is the kind of shoot-from-the-hip, junk journalism that's rampant on the Internet, intended to throw red meat to ridicule-hungry trolls. Yet it can be potentially devastating to people making an honest living creating products that deliver real value to users."
The ThiPad Hands-Free Tablet Stand straps securely to the leg just above the knee, with a non-slip surface that snugly holds any-sized tablet computer, including iPads, Kindles, Nooks, Androids, smartphones, and other mobile devices, in their cases or out. It provides hours of comfortable viewing, working, typing, playing games, or practicing with a musical instrument, without tying up the hands or tiring out the arms.
McTigue invites reputable journalists and media organizations to request a review sample of the product so they can give it a fair and impartial test run. "Then they can love it, hate it, pan it, or praise it, as they see fit," he says. "But we think they'll be surprised at how securely the new ThiPad fits and how beautifully it performs."
To request a review sample, contact inquiry@thipad.com or 203-254-7789. To learn more visit http://thipad.com.
ThiPad.com is the creator and manufacturer of the new ThiPad Hands-Free Tablet Stand.
"Worst Ever" Slam by Yahoo! Boosts Sales of New ThiPad Tablet Stand
Included among the "Worst Ever" iPad accessories by a Yahoo! shopping blog, the ThiPad Hands-Free Tablet Stand actually experienced a sharp spike in sales when intrigued readers flocked to the ThiPad.com site.
2013-06-03
ELSE PRESS RELEASES FROM THIS DATE:
Some patients with treatment-resistant colorectal cancers may have a new option
2013-06-02
PHILADELPHIA — A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET inhibitor drugs.
The MET gene is known to be amplified in about ...
Addition of bevacizumab to initial treatment for brain tumors does not extend patients' lives
2013-06-02
Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival,. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting.
Chicago, Illinois—GBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is ...
New cancer drug shows promise for treating advanced melanoma
2013-06-02
Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.
The results were presented at the 2013 meeting of the American Society of Clinical Oncology today in Chicago by Dr. Antoni Ribas, professor of medicine in the UCLA division of hematology-oncology, who led the research. Following Ribas' presentation, the study was published online ahead of press in the New England Journal of Medicine. ...
Test helps target glioblastoma patients most likely to benefit from bevacizumab
2013-06-02
CHICAGO, IL – A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®), according to new research from The University of Texas MD Anderson Cancer Center.
The results of the study were presented today at the annual meeting of the American Society of Clinical Oncology.
This study is associated with RTOG 0825, a large multi-center Phase III trial that evaluated the addition of bevacizumab to standard chemoradiation and maintenance temozolomide in treating newly diagnosed glioblastoma. Half of the participants ...
Combination of drugs produces dramatic tumor responses in advanced melanoma patients
2013-06-02
CHICAGO, JUNE 2, 2013 — The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Several patients experienced tumor shrinkage of more than 80 percent within ...
Bevacizumab offers no benefit for newly diagnosed glioblastoma, M.D. Anderson-led study finds
2013-06-02
Chicago, IL – The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.
The study was presented today on the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting by Mark Gilbert, M.D., professor in MD Anderson's Department of Neuro-Oncology.
Glioblastoma is both the most common and lethal form of brain ...
US oncologists report high career satisfaction, yet many suffer symptoms of burnout
2013-06-02
CHICAGO -- Even though a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, a Mayo Clinic-led study has found. The study was released during the American Society of Clinical Oncology's annual meeting in Chicago.
"Oncology can be a tremendously rewarding area of medicine, but caring for patients with cancer is also demanding and stressful," says lead author Tait Shanafelt, M.D., a Mayo Clinic hematologist/oncologist. "Oncologists work long hours, supervise the administration of highly toxic ...
Abnormalities in HER2 gene found in wide variety of advanced cancers
2013-06-02
(CHICAGO) The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression — among them mutations, amplifications, substitutions, and translocations — have been found in 14 different advanced solid tumors.
The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of these tumors might benefit from the three anti-HER2 therapies now in clinical use.
"No ...
Therapy that heats and destroys bone tumors eases patients' pain
2013-06-02
(CHICAGO) Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists. Results of a clinical trial on the new therapy, presented by a researcher at Jefferson's Kimmel Cancer Center, is being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
Mark Hurwitz, MD, Director of Thermal Oncology for the Department of Radiation Oncology at Thomas Jefferson University and Hospital reported that the treatment, ...
Targeted therapy sorafenib shows success in advanced differentiated thyroid cancer patients
2013-06-02
CHICAGO – The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting (Abstract #4).
If approved for use in thyroid cancer patients by the Food and Drug Administration, sorafenib (Nexavar), a kinase inhibitor that mediates tumor ...
LAST 30 PRESS RELEASES:
3 Ways to reduce child sexual abuse rates
A third of children worldwide forecast to be obese or overweight by 2050
Contraction inhibitors after 30 weeks have no effect on baby's health
Nearly 1 in 5 US college athletes reports abusive supervision by their coaches
THE LANCET: More than half of adults and a third of children and adolescents predicted to have overweight or obesity by 2050
Ideal nitrogen fertilizer rates in Corn Belt have been climbing for decades, Iowa State study shows
Survey suggests people with disabilities may feel disrespected by health care providers
U-Michigan, UC Riverside launch alliance to promote hydrogen-fueled internal combustion engines
New insights into network power response: Unveiling multi-timescale characteristics
Simple algorithm helps improve treatment, reduce disparities in MS
Despite high employment rates, Black immigrants in the United States more likely to be uninsured, USC study shows
Research supports move toward better tailoring stroke rehabilitation
Imagining future events changes brain to improve healthy decision-making, new study indicates
Turning plastic waste into valuable resources: A new photocatalytic approach
Sea otters help kelp forests recover — but how fast depends on where they are
Study links intense energy bursts to ventilator-induced lung injury
Uncovering the protein complex critical to male fertility
Scientists discover how a naturally occurring mechanism hampers fertility
Integrated framework for ecological security: A case study of the Daqing river basin
New design paradigm boosts reconfigurable intelligent surface efficiency
Long-term cocaine use may increase impulsivity
How London’s Ultra Low Emission Zone is changing the school run
Breakthrough CRISPR-based test offers faster, more accurate diagnosis for fungal pneumonia
3D-printed knee implants improves quality and reliability
UC San Diego innovators to spotlight transformative science at SXSW 2025
Burning question: How to save an old-growth forest in Tahoe
SwRI, U-Michigan engineers create more effective burner to reduce methane emissions
Dental implants still functional after forty years
A hot droplet can bounce across a cool pan, too
Synthetic microbiome therapy suppresses bacterial infection without antibiotics
[Press-News.org] "Worst Ever" Slam by Yahoo! Boosts Sales of New ThiPad Tablet StandIncluded among the "Worst Ever" iPad accessories by a Yahoo! shopping blog, the ThiPad Hands-Free Tablet Stand actually experienced a sharp spike in sales when intrigued readers flocked to the ThiPad.com site.